Antiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1

Journal of Acquired Immune Deficiency Syndromes

Volumn 66, Issue 1, 2014, Pages 65-73

  Herold, Betsy C ^a   Dezzutti, Charlene S ^b,c   Richardson, Barbra A ^d,e   Marrazzo, Jeanne ^d   Mesquita, Pedro M M ^a   Carpenter, Colleen ^a   Huber, Ashley ^a   Louissaint, Nicolette ^f   Marzinke, Mark A ^f   Hillier, Sharon L ^b,c   Hendrix, Craig W ^f  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e USA   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

HIV; HSV 2; mucosal immune mediators; pre exposure prophylaxis; tenofovir

Indexed keywords

DEFENSIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 6; INTERLEUKIN 8; LACTOFERRIN; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; PROTEIN; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; TENOFOVIR;

ANTIVIRAL ACTIVITY; ARTICLE; BLOOD LEVEL; CERVICOVAGINAL LAVAGE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; GENITAL SYSTEM; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LAVAGE; MACROPHAGE; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; MEDIATOR RELEASE; OBSERVATION; PRIORITY JOURNAL; PROPHYLAXIS; VAGINAL LAVAGE; VAGINAL SECRETION;

ADENINE; ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, ORAL; ADULT; ANTI-HIV AGENTS; BODILY SECRETIONS; CHEMOPREVENTION; FEMALE; GENITALIA, FEMALE; HERPESVIRUS 2, HUMAN; HIV-1; HUMANS; MASS SPECTROMETRY; MICROBIAL SENSITIVITY TESTS; ORGANOPHOSPHONATES;

EID: 84898544900     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000110     Document Type: Article

References (37)

1. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367: 399-410.
2. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423-434.
3. Marrazzo JM, Ramjee G, Nair G, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral Tenofovir/Emtricitabine, or vaginal tenofovir gel in the VOICE study (MTN 003). Paper presented at: 20th Conference on Retroviruses and Opportunistic Infections, March 4, 2013; Atlanta, GA.
4. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367: 411-422.
5. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168-1174.
6. Anton PA, Cranston RD, Kashuba A, et al. RMP-02/MTN-006: a phase 1 Rectal safety, Acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses. 2012.
7. Venkataraman N, Cole AL, Svoboda P, et al. Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid. J Immunol. 2005;175:7560-7567.
8. Keller MJ, Madan RP, Torres NM, et al. A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS One. 2011; 6:e16475.
9. John M, Keller MJ, Fam EH, et al. Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection. J Infect Dis. 2005; 192:1731-1740.
10. Ghosh M, Fahey JV, Shen Z, et al. Anti-HIV activity in cervical-vaginal secretions from HIV-positive and -negative women correlate with innate antimicrobial levels and IgG antibodies. PLoS One. 2010;5:e11366.
11. Anderson PL, Kiser JJ, Gardner EM, et al. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother. 2011;66:240-250.
12. Hendrix CW, Chen BA, Guddera V, et al. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One. 2013; 8:e55013.
13. Blish CA, McClelland RS, Richardson BA, et al. Genital Inflammation Predicts HIV-1 Shedding Independent of Plasma Viral Load and Systemic Inflammation. J Acquir Immune Defic Syndr. 2012;61: 436-440.
14. Roberts L, Passmore JA, Mlisana K, et al. Genital tract inflammation during early HIV-1 infection predicts higher plasma viral load set point in women. J Infect Dis. 2012;205:194-203.
15. Keller MJ, Herold BC. Impact of microbicides and sexually transmitted infections on mucosal immunity in the female genital tract. Am J Reprod Immunol. 2006;56:356-363.
16. Amsel R, Totten PA, Spiegel CA, et al. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983; 74:14-22.
17. Keller MJ, Guzman E, Hazrati E, et al. PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. AIDS. 2007;21:467-476.
18. Mesquita PM, Rastogi R, Segarra TJ, et al. Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection. J Antimicrob Chemother. 2012.
19. Naranbhai V, Abdool Karim SS, AltfeldM, et al. Innate immune activation enhances HIV acquisition in women, Diminishing the effectiveness of tenofovir microbicide gel. J Infect Dis. 2012;206:993-1001.
20. Schwartz JL, Rountree W, Kashuba AD, et al. A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. PLoS One. 2011;6:e25974.
21. Sharkey DJ, Macpherson AM, Tremellen KP, et al. TGF-beta mediates proinflammatory seminal fluid Signaling in human cervical epithelial cells. J Immunol. 2012;189:1024-1035.
22. Sharkey DJ, Macpherson AM, Tremellen KP, et al. Seminal plasma differentially regulates inflammatory cytokine gene expression in human cervical and vaginal epithelial cells. Mol Hum Reprod. 2007; 13:491-501.
23. Sharkey DJ, Tremellen KP, Jasper MJ, et al. Seminal fluid induces leukocyte recruitment and cytokine and chemokine mRNA expression in the human cervix after coitus. J Immunol. 2012;188:2445-2454.
24. Karim SA. CAPRISA 004 Two Years on: Ten Key Lessons & Their Implications. Presented at Microbicides 2012, April 15, 2012; Sydney, Australia.
25. Robbins BL, Srinivas RV, Kim C, et al. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother. 1998;42:612-617.
26. Balzarini J, Van Herrewege Y, Vanham G. Metabolic activation of nucleoside and nucleotide reverse transcriptase inhibitors in dendritic and Langerhans cells. AIDS. 2002;16:2159-2163.
27. Gao WY, Agbaria R, Driscoll JS, et al. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 29,39-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem. 1994;269: 12633-12638.
28. Garcia-Lerma JG, Aung W, Cong ME, et al. Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors. J Virol. 2011;85:6610-6617.
29. Cihlar T, Ho ES, Lin DC, et al. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids. 2001;20:641-648.
30. Tan DH, Kaul R, Raboud JM, et al. No impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding in HIV-infected adults. AIDS. 2011;25:207-210.
31. Keller MJ, Madan RP, Shust G, et al. Changes in the soluble mucosal immune environment during genital herpes outbreaks. J Acquir Immune Defic Syndr. 2012;61:194-202.
32. Shust GF, Cho S, Kim M, et al. Female genital tract secretions inhibit herpes simplex virus infection: correlation with soluble mucosal immune mediators and impact of hormonal contraception. Am J Reprod Immunol. 2010;63:110-119.
33. Madan RP, Carpenter C, Fiedler T, et al. Altered biomarkers of mucosal immunity and reduced vaginal Lactobacillus concentrations in sexually active female adolescents. PLoS One. 2012;7:e40415.
34. Dezzutti CS, Rohan LC, Wang L, et al. Reformulated tenofovir gel for use as a dual compartment microbicide. J Antimicrob Chemother. 2012; 67:2139-2142.
35. Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP, et al. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One. 2010;5:e9310.
36. Maagaard A, Kvale D. Mitochondrial toxicity in HIV-infected patients both off and on antiretroviral treatment: a continuum or distinct underlying mechanisms? J Antimicrob Chemother. 2009;64: 901-909.
37. Ray AS, Cihlar T, Robinson KL, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother. 2006;50: 3297-3304.